Table 1

Results of progression free survival analysis of urinary bladder tumours, TaT1 urothelial cell carcinomas

VariableNProgressedCensored% Progression free survivalLog rankp ValueHR95% CI
Line 1, 1st figure: subgroup 1 reference value; 2nd figure: subgroup 2 v 1; 3rd figure: subgroup 3 v 1; 4th figure: subgroup 4 v 1.
CI, confidence interval; DI, DNA index; HR, hazards ratio; N, number; MAI, mitotic activity index; MNA10, mean area of the 10 largest nuclei; SPF, S phase fraction.
Models in the total group (n=171)
Sex
    Male133812593.91.90.162.30.7 to 6.6
    Female3853386.4
Age
    <604724595.71.90.601.0
    60–674534293.31.60.3 to 9.9
    67–764253788.12.80.6 to 14.9
    >763733491.91.90.3 to 11.1
TaT1
    Ta132812493.92.00.152.20.7 to 6.7
    T13953487.2
Multicentricity
    Yes1921789.50.40.550.60.1 to 2.9
    No1521114192.5
Carcinoma in situ
    Yes41375.01.70.190.30.0 to 2.2
    No1671215592.8
Original grade
    13813797.414.10.00091.0
    27827697.41.00.9 to 11.0
    355104581.88.01.0 to 62.6
Revised grade
    140040100.011.80.00261.0
    26936695.6InfiniteInfinite
    362105283.3InfiniteInfinite
Treatment
    Low risk28028100.017.40.00021.0
    Intermediate7517498.7InfiniteInfinite
    High risk68125682.4InfiniteInfinite
Flow cytometry
    DI = 1.00102210098.013.60.000210.12.2 to 45.9
    All others69115884.1
    DI <1.3113311097.413.60.00027.92.2 to 28.9
    All others58104882.8
Image cytometry
    DI = 1.00104210298.113.80.000210.22.2 to 46.0
    All others67115683.6
    DI <1.3109210798.216.10.000111.62.6 to 52.5
    All others62115182.3
    DI >1.3 and SPF >16.23382575.816.80.00007.72.3 to 22.4
    All others138513396.4
MNA10
    <90.041041100.036.90.00001.0
    90.0–119.042042100.01.0Infinite
    119.1–179.038038100.01.0Infinite
    >179.050133774.0375.0Infinite
    <170.01210121100.036.860.0000372.8Infinite
    >170.050133774.0
MAI
    <248048100.048.90.00001.0
    2–1035035100.01.0Infinite
    10–3046046100.01.0Infinite
    >3042132969.1916.7Infinite
    ≤301290129100.048.90.0000909.5Infinite
    >3042132969.0
Ki67 area%
    <5.044044100.045.90.00001.0
    5.0–13.044044100.01.0Infinite
    13.0–26.039039100.01.0Infinite
    >26.044133170.45719.0Infinite
    ≤25.01270127100.045.90.0000712.3Infinite
    >25.044133170.45
p53 area%
    <8.239039100.026.60.00001.0
    8.2–17.144044100.01.0Infinite
    17.1–36.04224095.2InfiniteInfinite
    >36.046113576.1InfiniteInfinite
MNA10 (170) and Ki67 (25)
    All others1350135100.060.80.00002216.5Infinite
    >170.0 >25.036132363.9
MNA10 (170) and MAI (30)
    All others1380138100.069.30.00004215.3Infinite
    >170.0 >3033132060.6
Ki67 (25) and p53 (35.2)
    All others141213998.652.70.000033.9Infinite
    >25.0 >35.230111963.3
Models within the BCG treated high risk subgroup (n=68)
MNA10 (170) MAI (30) low36036100.016.60.000077.8Infinite
MNA10 (170) MAI (30) high32122062.5
MNA10 (170) Ki67 (25) low34034100.014.30.000095.4Infinite
MNA10 (170) Ki67 (25) high34122264.7